A new initiative by the Centers for Medicare & Medicaid Services could soon allow some patients enrolled in government-backed health insurance programs to receive partial coverage for hemp-based products. The proposal would allow eligible participants to access up to $500 annually in qualifying CBD products, with initial phases possibly starting as early as April 1.
The program focuses primarily on CBD products but permits limited levels of THC. Officials noted that guidelines may be revised depending on anticipated changes to federal hemp regulations.
The move follows a December executive order signed by President Donald Trump directing the attorney general to move forward with reclassifying cannabis under federal law. That directive also included measures to expand access to CBD products. In response, CMS released new guidance outlining how its innovation center programs could support a controlled rollout of hemp-derived CBD coverage.
Under the pilot, participating providers would need to ensure that all products are sourced from regulated farms and meet quality standards. Approved products must be formulated for oral use and undergo testing to confirm cannabinoid levels. The guidelines cap delta-9 THC concentration at 0.3%, with a maximum of 3 mg of THC per serving.
CMS added that participating organizations will be allowed to discuss the potential use of qualifying hemp products with beneficiaries as part of broader symptom management strategies. The organizations must also take part in one of three Innovation Center models that include Beneficiary Engagement Incentives tied to substance access.
The eligible models include the Long-term Enhance ACO Design Model, the Enhancing Oncology Model, and the ACO REACH Model. Organizations in the first category are scheduled to begin offering CBD-related benefits on Jan. 1, 2027. The latter two may begin on April 1, 2026.
Before providing coverage, participating groups must opt into the incentive program and submit a detailed implementation plan to CMS. This plan must outline the specific products being offered, dosage guidelines, distribution frequency, patient eligibility criteria, and oversight measures. Approval from CMS is required before any benefits can be provided.
The proposal has already drawn attention due to a separate federal law expected to redefine hemp starting in November. The measure would impose stricter limits on THC content, potentially restricting many products currently allowed under the 2018 Farm Bill. Industry representatives have warned that the new limits could significantly disrupt the market for hemp products.
CMS clarified that for the purposes of this program, eligible products must comply with existing federal definitions established under the 2018 Farm Bill. The agency specifically excludes inhalable items, products exceeding the set THC limits, and substances containing synthetic or non-naturally occurring cannabinoids.
Officials emphasized that the initiative does not alter federal drug scheduling laws or permit access to substances classified as Schedule I. In addition, all covered products must align with local and state regulations, a requirement that could complicate implementation, given that several states have already introduced restrictions on hemp-derived products.
The agency also noted that qualifying cannabinoid treatments must be provided directly by licensed physicians from a participating group. Patients will not be allowed to purchase products independently and seek reimbursement.
This CMS program is likely to be watched closely by marijuana firms like Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) as it is rolled out around the U.S.
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.CannabisNewsWire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer
CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CannabisNewsWire is powered by IBN
